Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Part of paid clinical trials in San Francisco, California.

Sponsor
Peter Ljubenkov, MD
Study ID
NCT05184569
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Semantic Dementia

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Verdiperstat — DRUG
    Oral, extended release (ER) tablet

Study Details

The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.

Key Dates

Start date
Apr 14, 2022
Status verified
Oct 2025
Primary completion
Jun 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Verdiperstat
    Verdiperstat 2 tablets twice daily (600mg total daily) by mouth for 24 weeks.
  • Placebo Comparator: Placebo
    Placebo 2 tablets twice daily by mouth for 24 weeks.

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events [ Time Frame: 24 Weeks ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
UCSF Memory and Aging CenterSan FranciscoCalifornia94158
Caroline Sirna, MSc
[email protected]
415-514-9643
Karin Snowberg, MA
[email protected]
415-476-8845
Northwestern UniversityChicagoIllinois60611
Caila Ryan, MS
[email protected]
312-503-5674
Kailey Zajicek, BS, BA
[email protected]
312-503-6209
Ian Grant, MD (PRINCIPAL_INVESTIGATOR)
Mayo ClinicRochesterMinnesota55905
Kevin Nelson
[email protected]
507.284.1324
David Knopman, MD (PRINCIPAL_INVESTIGATOR)
University of PennsylvaniaPhiladelphiaPennsylvania19104
Dahlia Kamel, MS
[email protected]
215-662-6134
Alex Tavani
[email protected]
215-662-2060
David Irwin, MD (PRINCIPAL_INVESTIGATOR)
Houston Methodist Hospital - Nantz National Alzheimer CenterHoustonTexas77030
Manuel Navarro, RN
[email protected]
346-238-0083
Victoria Arbones, RN
[email protected]
713-441-7650
Belen Pascual, PhD (PRINCIPAL_INVESTIGATOR)
Joseph Masdeu, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
UCSF Memory and Aging Center· San Francisco, CANorthwestern University· Chicago, ILMayo Clinic· Rochester, MNUniversity of Pennsylvania· Philadelphia, PAHouston Methodist Hospital - Nantz National Alzheimer Center· Houston, TX

Related Studies